Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Valion Bio Chair Thomas Jensen on Advancing Entolimod

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

Valion Bio appointed Thomas Jensen as Board Chair to advance Entolimod, its investigational treatment for acute radiation syndrome (ARS), leveraging approximately $35.6 million in non-dilutive U.S. government funding and regulatory fast-track designations. Jensen aims to explore Entolimod's potential in cancer supportive care while Valion's wholly owned CDMO, Velocity Bioworks, supports manufacturing.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech firm can now eye ARS treatments with faster FDA routes and government funding backing, but prepare for rigorous development demands as this pathway accelerates but does not guarantee approval.

◆ Coverage

1 source · 5 Oct 2026

◆ Related on Wire

◆ Topics

Biotechacute-radiation-syndromeentolimodfda-fast-trackorphan-drugcdmobiotech-leadership